STOCK TITAN
  1. Home
  2. News
  3. BAX

Baxter International Inc. - BAX STOCK NEWS

Welcome to our dedicated news page for Baxter International (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Baxter International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Baxter International's position in the market.

News
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
Rhea-AI Summary
Baxter International Inc. announces the launch of five new injectable products in the U.S., reinforcing its focus on differentiated offerings in critical therapeutic areas. The products aim to enhance patient safety and provide convenience to healthcare professionals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News
Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
Rhea-AI Summary
Baxter International Inc. (BAX) will discuss its first-quarter 2024 financial results in a conference call on May 2, 2024. The call can be accessed through a provided link and Baxter's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
conferences earnings
-
News
Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
Rhea-AI Summary
Baxter International Inc. announces FDA clearance for Novum IQ large volume infusion pump, enhancing patient care efficiency with advanced connected solutions. The platform integrates LVP and SYR pumps with Dose IQ Safety Software and IQ Enterprise Connectivity Suite, streamlining operations and improving safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
clinical trial
News
Baxter to Host Annual Meeting of Stockholders in Virtual Format
Rhea-AI Summary
Baxter International Inc. to Host Virtual Annual Meeting of Stockholders in 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
conferences
-
News
Baxter to Present at Raymond James 45th Annual Institutional Investors Conference
Rhea-AI Summary
Baxter International Inc. (BAX) will present at the Raymond James 45th Annual Institutional Investors Conference on March 4, 2024. Joel Grade, the CFO, will present at 4:00 p.m. ET. The webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
conferences
-
News
Baxter Declares Quarterly Dividend
Rhea-AI Summary
Baxter International Inc. (BAX) declares a quarterly cash dividend of $0.29 per share, with an annual rate of $1.16, payable on April 1, 2024, to stockholders of record as of March 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
dividends
News
Baxter Reports Fourth-Quarter and Full-Year 2023 Results
Rhea-AI Summary
Baxter International Inc. reported a 4% increase in fourth-quarter sales, reaching $3.89 billion. Full-year sales grew by 2% to $14.81 billion. The company's U.S. GAAP diluted EPS from continuing operations was $0.14 for the fourth quarter and ($0.15) for the full year. Adjusted diluted EPS from continuing operations was $0.88 for the fourth quarter and $2.60 for the full year. Baxter is preparing for the proposed separation of its Kidney Care segment into a standalone company named Vantive. The company reported strong sales growth in the Healthcare Systems and Technologies segment, while Kidney Care sales declined. Baxter also highlighted key strategic priorities and corporate responsibility initiatives for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
earnings
-
News
Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors
Rhea-AI Summary
Baxter International Inc. (BAX) will host a conference call to discuss its fourth-quarter 2023 financial results on February 8, 2024, at 7:30 a.m. Central Time. Participants can pre-register for the call and access the webcast through Baxter's website. The call will be recorded and is copyrighted material.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences earnings
-
News
Baxter Advances First Intravenous (IV) Bag Recycling Pilot for U.S. Hospitals
Rhea-AI Summary
Baxter International Inc. (NYSE:BAX) has successfully completed the first phase of its intravenous (IV) bag recycling program pilot in collaboration with Northwestern Memorial Hospital, diverting more than six tons of polyvinyl chloride (PVC) IV bag waste from landfills. This innovative program demonstrates Baxter's commitment to corporate responsibility and waste reduction, with plans to expand the program to support scalability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
none
News
Baxter to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Baxter International Inc. (BAX) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. José (Joe) E. Almeida, Chairman, President, and CEO, will present at 10:30 a.m. Pacific Time. The live webcast can be accessed at www.baxter.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
conferences
Stock BAX logo
Baxter International Inc.

NYSE:BAX

BAX Rankings

#501 Ranked by Market Cap
#4368 Ranked by Stock Gains
#1155 Ranked by Dividends

BAX Stock Data

20.15B
505.48M
0.37%
92.39%
1.5%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Deerfield

About BAX

baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.